Table 3 Individual antibody responses to MB2 recombinant peptides of the B domain as determined by immunoblot analysis.

Volunteer serum

Volunteer #1 (protected)

- ^b

++ ^b

-/+ ^b

Volunteer #3 (protected)

-

++

-/+

Volunteer #5 (protected)

-

++

-/+

Volunteer #7 (protected)

-

++

-/+

WRAIR #1 (protected)

-

++

-/+

WRAIR #4 (not protected)

-

-

-

WRAIR #5 (not protected)

-

-

-

WRAIR #6 (not protected)

-

-

-

Kenyan serum

Smear negative

MB2-A ^a

MB2-B ^a

MB2-C ^a

Age

(yrs)

CSP

AU ^d

TRAP

AU ^d

^c KU 036

-

++

+

29

1.77

2.35

KU 071

-

++

+++

18

1.24

2.08

KU 081

-

+

++

34

1.01

1.23

KU 069

-

+

++

18

0.55

1.31

KU 079

-

-/+

++

80

1.0

2.63

KU 083

-

-/+

+++

45

4.28

4.80

KU 163

-

++

-/+

18

1.75

1.46

KU 202

-

-

+

30

2.22

2.22

KU 205

-

-/+

-/+

44

1.81

1.17

Smear positive, asymptomatic

KU 118

-

-

-

23

1.94

1.85

KU 044

-

+

-

6

0.75

0.79

KU 048

-

-

+

6

0.61

0.62

KU 076

-

-

-/+

6

1.29

0.72

KU 001

-

++

++

2

1.11

1.43

KU 049

-

-

-

6

1.64

0.66

KU 025

-

-

-

6

0.42

0.26

Smear positive, symptomatic

KU 064

-

-

-

27

1.38

2.40

KU 070

-

+

-

18

1.41

1.59

KU 157

-

+

+++

20

1.64

1.37

KU 158

-

+

++

26

ND

ND

KU 165

-

-

-

26

0.34

0.10

KU 172

-

-/+

++

22

ND

ND

KU 199

-

+

-/+

19

ND

ND

KU 203

-

-

-/+

30

1.34

1.0

KU 207

-

-

+

19

ND

ND

KU 234

-

+

-/+

42

ND

ND

KU 162

-

+

+++

6

ND

ND

KU 062

-

-

-

6

0.87

1.85

KU 161

-

-

-/+

7

0.67

0.88

KU 041

-

-

-/+

6

1.62

0.71

KU 037

-

++

-/+

60

1.36

1.52

KU 072

-

-/+

-/+

24

0.59

1.0

KU 075

-

+

++

32

0.72

1.35

KU 080

-

-/+

+

34

0.87

1.50

KU 088

-

-

-

70

1.01

0.57

KU 145

-

+

+

40

3.01

2.56

KU 155

-

-

++

37

0.53

0.38

KU 174

-

+

+

22

2.27

1.90

KU 183

-

-/+

++

23

0.30

0.36

KU 067

-

-

+

6

1.90

2.95

KU 084

-

++

+

2

0.40

1.277